Vapotherm, Inc. (NYSE:VAPO) to Post Q3 2022 Earnings of ($0.82) Per Share, William Blair Forecasts
Vapotherm, Inc. (NYSE:VAPO) to Post Q3 2022 Earnings of ($0.82) Per Share, William Blair Forecasts
Vapotherm, Inc. (NYSE:VAPO – Get Rating) – Investment analysts at William Blair reduced their Q3 2022 earnings per share estimates for shares of Vapotherm in a note issued to investors on Wednesday, August 3rd. William Blair analyst M. Kaczor now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their prior estimate of ($0.74). William Blair has a "Market Perform" rating on the stock. The consensus estimate for Vapotherm's current full-year earnings is ($3.28) per share. William Blair also issued estimates for Vapotherm's Q4 2022 earnings at ($0.69) EPS, Q1 2023 earnings at ($0.59) EPS, Q2 2023 earnings at ($0.58) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.43) EPS and FY2023 earnings at ($2.18) EPS.
Vaptherm，Inc.(纽约证券交易所代码：VAPO-GET Rating)-威廉·布莱尔的投资分析师在8月3日星期三发给投资者的一份报告中下调了对Vaptherm股票2022年第三季度每股收益的预期。威廉·布莱尔分析师M.Kaczor现在预计，该公司本季度每股收益将为0.82美元，低于此前预期的0.74美元。威廉·布莱尔对该股的评级为“市场表现”。对Vaptherm目前全年收益的普遍估计是每股3.28美元。威廉·布莱尔还发布了对Vaptherm 2022年第四季度每股收益(0.69美元)、2023年第一季度每股收益(0.59美元)、2023年第二季度每股收益(0.58美元)、2023年第三季度每股收益(0.58美元)、2023年第四季度每股收益(0.43美元)和2023财年每股收益(2.18美元)的预期。
Other analysts have also recently issued research reports about the company. Canaccord Genuity Group cut Vapotherm from a "buy" rating to a "hold" rating and lowered their price target for the stock from $12.00 to $5.00 in a research report on Friday, May 6th. BTIG Research cut Vapotherm from a "buy" rating to a "neutral" rating in a research report on Thursday. Canaccord Genuity Group lowered Vapotherm from a "buy" rating to a "hold" rating and reduced their price objective for the company from $12.00 to $5.00 in a research note on Friday, May 6th. Finally, Piper Sandler reduced their price objective on Vapotherm from $2.50 to $2.00 and set an "underweight" rating for the company in a research note on Thursday. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. Based on data from MarketBeat, Vapotherm has an average rating of "Hold" and a consensus target price of $4.75.
其他分析师最近也发布了关于该公司的研究报告。在5月6日星期五的一份研究报告中，Canaccel Genuity Group将Vaptherm的评级从买入下调至持有，并将该股的目标价从12.00美元下调至5.00美元。BTIG Research周四在一份研究报告中将Vaptherm的评级从“买入”下调至“中性”。Cancord Genuity Group在5月6日星期五的一份研究报告中将Vaptherm的评级从“买入”下调至“持有”，并将该公司的目标价从12.00美元下调至5.00美元。最后，派珀·桑德勒将Vaptherm的目标价从2.50美元下调至2.00美元，并在周四的一份研究报告中为该公司设定了“减持”评级。一名投资分析师对该股的评级为卖出，四名分析师对该公司的评级为持有。根据MarketBeat的数据，Vaptherm的平均评级为持有，共识目标价为4.75美元。
Vapotherm Stock Performance
Vaptherm股票表现
Insider Buying and Selling at Vapotherm
Vaptherm的内部买入和卖出
In related news, Director Anthony L. Arnerich acquired 10,000 shares of Vapotherm stock in a transaction on Wednesday, June 1st. The stock was acquired at an average price of $3.06 per share, for a total transaction of $30,600.00. Following the purchase, the director now owns 53,374 shares of the company's stock, valued at approximately $163,324.44. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders purchased 35,000 shares of company stock worth $106,100. Insiders own 12.80% of the company's stock.
在相关新闻中，董事安东尼·L·阿内里奇在6月1日星期三的一笔交易中收购了10,000股Vaptherm股票。这只股票是以每股3.06美元的平均价格收购的，总交易额为30,600.00美元。收购完成后，董事现在拥有该公司53,374股股票，价值约163,324.44美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的，通过这个超级链接可以访问微博。在上个季度，内部人士购买了3.5万股公司股票，价值10.61万美元。内部人士持有该公司12.80%的股份。
Hedge Funds Weigh In On Vapotherm
对冲基金参与Vaptherm
Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA increased its stake in shares of Vapotherm by 18.0% in the 4th quarter. BNP Paribas Arbitrage SA now owns 4,907 shares of the company's stock valued at $102,000 after purchasing an additional 747 shares in the last quarter. Taylor Frigon Capital Management LLC increased its stake in shares of Vapotherm by 1.3% in the 1st quarter. Taylor Frigon Capital Management LLC now owns 174,752 shares of the company's stock valued at $2,429,000 after purchasing an additional 2,218 shares in the last quarter. RiverVest Venture Management LLC increased its stake in shares of Vapotherm by 0.6% in the 4th quarter. RiverVest Venture Management LLC now owns 407,166 shares of the company's stock valued at $8,432,000 after purchasing an additional 2,535 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Vapotherm by 2.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 165,834 shares of the company's stock valued at $2,306,000 after purchasing an additional 3,209 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Vapotherm by 60.7% in the 1st quarter. MetLife Investment Management LLC now owns 14,161 shares of the company's stock valued at $197,000 after purchasing an additional 5,351 shares in the last quarter. Hedge funds and other institutional investors own 69.67% of the company's stock.
几家机构投资者和对冲基金最近调整了对该公司的持股。法国巴黎银行套利公司在第四季度增持了18.0%的Vaptherm股票。法国巴黎银行套利公司现在持有该公司4,907股股票，价值10.2万美元，在上个季度又购买了747股。Taylor Frigon Capital Management LLC在第一季度增持了1.3%的Vaptherm股票。Taylor Frigon Capital Management LLC现在拥有174,752股该公司股票，价值2,429,000美元，上个季度又购买了2,218股。RiverVest Venture Management LLC在第四季度增持了Vaptherm股票0.6%。RiverVest Venture Management LLC现在拥有407,166股该公司的股票，价值8,432,000美元，上个季度又购买了2,535股。嘉信理财第一季度增持Vaptherm股票2.0%。嘉信理财目前持有165,834股该公司股票，价值2,306,000美元，该公司在上个季度又购买了3,209股。最后，大都会人寿投资管理有限责任公司在第一季度增持了60.7%的Vaptherm股票。大都会人寿投资管理有限责任公司现在拥有14,161股该公司的股票，价值19.7万美元，上个季度又购买了5,351股。对冲基金和其他机构投资者持有该公司69.67%的股票。
Vapotherm Company Profile
Vaptherm公司简介
(Get Rating)
(获取评级)
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Vaptherm公司是一家医疗技术公司，专注于开发专有的高速治疗产品并将其商业化，用于在美国和国际上治疗不同年龄的呼吸窘迫患者。该公司提供精密流动系统，如Precision Flow Hi-VNI、Precision Flow Plus、Precision Flow Classic和Precision Flow Heliox，这些系统通过小口径鼻腔接口向患者高速输送加热、加湿和含氧的空气。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Vapotherm (VAPO)
- Can Airbnb Still Thrive in a Recession?
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- What to Expect from the Markets in a Recession
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 免费获取StockNews.com关于Vaptherm的研究报告(VAPO)
- 爱彼迎还能在经济衰退中茁壮成长吗？
- 康菲石油股价上涨，第二季度营收强劲
- 对衰退中的市场有什么期待
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.
接收《Vaptherm Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vaptherm和相关公司的最新新闻和分析师评级的每日简要摘要。